PNPLA2 and fatty liver disease: In the liver, SRA can also promote lipid metabolism via promoter activity suppression of adipose triglyceride lipase (ATGL) by targeting transcription factor FoxO1, thereby downregulating ATGL expression to promote hepatic steatosis (Chen et al., 2016).